These possibilities should be tested in animal models and could form the basis for novel therapeutic approaches to metabolic disease that employ SIRT1 modulators in combination with several thyromimetics that exhibit improved safety profiles relative to native thyroid hormones [34]. This evidence concerns the gene TG and Other metabolic disease.